Cholecystokinin and Psychiatric DisordersRole in Aetiology and Potential of Receptor Antagonists in Therapy

被引:0
|
作者
Jakov Shlik
Eero Vasar
Jacques Bradwejn
机构
[1] University of Tartu,Department of Psychiatry
[2] University of Tartu,Department of Physiology
[3] University of Toronto,Psychobiology and Clinical Trials Research Unit in Anxiety, Clarke Institute of Psychiatry
来源
CNS Drugs | 1997年 / 8卷
关键词
Panic Disorder; Cholecystokinin; Caerulein; Proglumide; Bioi Psychiatry;
D O I
暂无
中图分类号
学科分类号
摘要
Cholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in the highest levels in cortical and limbic structures and also in the basal ganglia. Two subtypes of CCK receptors have been described in the brain and gastrointestinal tissues. CCKA (alimentary subtype) receptors are mainly located in the gastrointestinal tract, regulating secretion of enzymes from the pancreas and emptying of the gallbladder. However, CCKA receptors are also found in several brain regions, with the highest densities in structures poorly protected by the haematoencephalic barrier (the area postrema, nucleus tractus solitarius and hypothalamus). The distribution of CCKB (brain subtype) receptors overlaps with the localisation of CCK and its mRNA in different brain areas, with the highest densities in the cerebral cortex, basal ganglia, nucleus accumbens and forebrain limbic structures.
引用
收藏
页码:134 / 152
页数:18
相关论文
共 50 条
  • [31] PROGLUMIDE AND BENZOTRIPT - MEMBERS OF A DIFFERENT CLASS OF CHOLECYSTOKININ RECEPTOR ANTAGONISTS
    HAHNE, WF
    JENSEN, RT
    LEMP, GF
    GARDNER, JD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (10): : 6304 - 6308
  • [32] Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists)
    de Tullio, P
    Delarge, J
    Pirotte, B
    CURRENT MEDICINAL CHEMISTRY, 1999, 6 (06) : 433 - 455
  • [33] MULTIPURPOSE RECEPTOR LIGANDS - BETA-CARBOLINE CHOLECYSTOKININ ANTAGONISTS
    EVANS, BE
    RITTLE, KE
    CHANG, RSL
    LOTTI, VJ
    FREEDMAN, SB
    FREIDINGER, RM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (05) : 867 - 870
  • [34] IDENTIFICATION OF STATE-SPECIFIC ANTAGONISTS FOR THE CHOLECYSTOKININ (CCK) RECEPTOR
    TALKAD, VD
    FORTUNE, KP
    SILEN, ML
    GARDNER, JD
    GASTROENTEROLOGY, 1994, 106 (04) : A845 - A845
  • [35] THE EFFECT OF CHOLECYSTOKININ-RECEPTOR ANTAGONISTS ON CHOLECYSTOKININ-STIMULATED BILE-FLOW IN DOGS
    WESTFALL, S
    ANDRUS, C
    SCHLARMAN, D
    KAMINSKI, DL
    SURGERY, 1991, 109 (03) : 294 - 300
  • [36] Corticotropin releasing factor receptor antagonists:: potential future therapy in gastroenterology?
    Taché, Y
    GUT, 2004, 53 (07) : 919 - 921
  • [37] LEUKOTRIENE RECEPTOR ANTAGONISTS AND BIOSYNTHESIS INHIBITORS - POTENTIAL BREAKTHROUGH IN ASTHMA THERAPY
    CHUNG, KF
    EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (07) : 1203 - 1213
  • [38] CCKB/gastrin receptor antagonists as potential drugs for peptic ulcer therapy
    Makovec, F
    DAmato, M
    DRUG DISCOVERY TODAY, 1997, 2 (07) : 283 - 293
  • [39] Studies on the synthesis of cholecystokinin a receptor antagonists .3. Synthesis and cholecystokinin a receptor inhibitory activities of naphthyl sulfone derivatives
    Ajisawa, Y
    Kitazawa, M
    Nakano, Y
    Tsubaki, A
    Ban, M
    Sato, K
    Okazaki, K
    Uchida, M
    Kobayashi, M
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1996, 116 (08): : 647 - 656
  • [40] Antiarrhythmic therapy with β-receptor antagonists
    Grönefeld G.C.
    Bänsch D.
    Herzschrittmachertherapie + Elektrophysiologie, 2010, 21 (4) : 222 - 227